tryptamine has been researched along with Depressive Disorder, Major in 4 studies
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fricke, J | 1 |
| Kargbo, R | 1 |
| Regestein, L | 1 |
| Lenz, C | 1 |
| Peschel, G | 1 |
| Rosenbaum, MA | 1 |
| Sherwood, A | 1 |
| Hoffmeister, D | 1 |
| Holt, A | 1 |
| Gaszner, P | 2 |
| Miklya, I | 2 |
3 reviews available for tryptamine and Depressive Disorder, Major
| Article | Year |
|---|---|
Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Binding Sites; Brain; Clonidine; Depressive Disord | 2003 |
The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
Topics: Benzofurans; Catecholamines; Depressive Disorder, Major; Humans; Mesencephalon; Neuroprotective Agen | 2004 |
Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Topics: Animals; Benzofurans; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Neuroprotect | 2006 |
1 other study available for tryptamine and Depressive Disorder, Major
| Article | Year |
|---|---|
Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin.
Topics: Agaricales; Biocatalysis; Depressive Disorder, Major; Humans; Psilocybe; Psilocybin; Tryptamines | 2020 |